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libraries. Five groups independently identified these autoantibodies in patients with thrombosis [1] , infertility [2, 3] , and rheumatoid arthritis (RA) [4, 5] . The diagnostic value of these autoantibodies as well as their role in pathophysiology remain to be elucidated even though two small studies suggest an association with RA [4, 5/. CAST is the endogenous inhibitor of the intracellular calcium-activated cysteine proteases calpain I and II (EC 3.4.22.1 7) [6, 7] . The inhibitor is colocalized with the calpains and is ubiquitous.
The cDNA sequence of human CAST predicts a 708 amino acid protein with a calculated molecular mass of 77 Wa [8] . CAST consists of five domains, four of which are homologous (20-35% identity) . In these four repeated domains a heptapeptide is found with a consensus sequence TIPPXYR, which is thought to be responsible for calpain inhibition [9] [10] [11] .
The unique N-terminal domain may vary in different tissues and cells [7] .
The calpains function by limited hydrolysis of specific proteins. These include cytoskeletal proteins such as spectrin and talin, cellular receptors such as the epidermab growth factor receptor, protein kinase C, and perhaps many as yet unknown substrates [6] . The calpains have been implicated in numerous regulatory processes including cytoskeletal rearrangement in the early phase of platelet aggregation or neutrophil degranulation, intracellular signal transduction (or modulation), and altered protein expression.
Therefore, the calpain system is likely to take part in a number of pathological processes. These might be caused by uncontrolled activation of the proteases, for example in platelet aggregation [12] and cartilage destruction in arthritic synovia [13-1 5] . Furthermore, extracellular sites of action for the calpains and a robe in tissue destruction, e.g., after hypoxia, have been discussed [16, 17] .
These CTG TGA GGT TTC TG  -3'   TCC ACT ACA GAA ACC  TC  -3   TCC ATT CTT AGG TGC TTT GG -3'   AGC  TCC AAA  GCA CCT AAG  -3'   TTA GTC ATC  TTT TGG CTT G -3'   TTA GTC ATC TAT TGG CTT GG -3'  TTA GTC AGC TTT TGG CTT GG -3' some cases hard to interpret, they are not suitable for clinical studies or routine diagnostics.
Therefore, an ELISA was developed that will permit the reliable analysis of large series of samples, which is a prerequisite for the further elucidation of the relevance of anti-CAST autoantibodies. CAST fragments were generated eitherdirectly by restriction enzyme cleavage of the cloned original cDNA fragment in pUC18 or by PCR amplification.
Materials and Methods

PATIENTS
They were inserted into the prokaryotic expression vector pXa I (Boehringer Mannheim) [19] in frame with the f3-gabactosidase gene and propagated in Escberichia coil XLlblue [20] . The primers used to generate the different CAST fusion proteins are shown in Fig. 1 with individual patient or proband sera. These sera were diluted 1:100 in 2 mL of blocking buffer and incubated for 1 h at room temperature with the blot strips, followed by three washings, 15 mm each, with 1 mL/L Tween 20 in PBS. Bound IgG was detected with a peroxidase-conjugated anti-human IgG (Dako), diluted 1:800 in blocking buffer. After three washings the blot was stained with the peroxidase substrate 3 -ammno-9-ethylcarbazole (Sigma, St. Louis, MO).
ELISA PLATES
Microtiterplates(Maxisorb; Nunc, Roskilde, Denmark) were coated overnight at room temperature with a synthetic peptide representing the C-terminal 27 amino acids of human CAST (Progen Biotechnik, Heidelberg, Germany) dissolved in PBS at 60 jLg/L (100 L/well).
Plates were subsequently rinsed with blocking buffer (PBS, 10 mL/L Tween 20, 50 g/L sucrose). They were then soaked for at least 10 mm in blocking buffer. After removal of excess buffer, the plates were dried by lyophibization seabed under vacuum and stored at 4 #{176}C. For the analysis of the precisionof the ELISA as well as largerpatient studies, a batch of 50 microtiter plates was prepared as described we cloned the cDNA fragment in frame into the prokaryotic expression vector pXa 1, which results in a 13-gabactosidase fusion protein of -126 Wa. Western blot analysis showed immunoreactivity of the patient'sserum with the expressed fusion protein but not with 13-gabactosidase alone (Fig. 3) , indicating that the serum contains antibodies specific for CAST. To further verify the specificity, the patient's serum was preincubated with soluble recombinant CAST. This abolished the reactivity in Western blots completely (Fig. 4) . The immunofluorescence pattern of the serum is unchanged by preincubation with recombinant CAST; this indicates that the fluores- complicated by a less-than-satisfactory reproducibility. Even though the majorityof positiveseracould be defined as either anti-CAST positive or negative,severalserawere detectedthat were positiveon one occasion and negativewhen the immunoblot was repeated. These results suggested to us that the W'esternblotassayisnot suitable forthe analysis of largepatient groups and clinical studies, even though it may be a usefultool to initially identify patients with autoantibodies to CAST.
EPITOPE MAPPING
The most obvious alternative to Western blot assays is a specific ELISA. The development of an ELISA requires the availability of pure antigen preparation.
The purification of large amounts of pure CAST from natural sources or from recombinant bacteria is technically difficult, particularly with respect to reproducibility of the preparation. Therefore, we decided to use a synthetic peptide or a mixture of peptides representing the major epitope(s) in CAST. In a first step the relevant epitopes on the protein had to be characterized.
The anti-CAST-positive sera were not able to precipitate the recombinant fusion protein in immunodiffusion assays, whereas a polycbonal anti-13-galactosidase antibody precipitated the p-galactosidase fusionprotein(datanot shown). This suggested to us that there might be only one epitope on the CAST fragment. For further epitope mapping, small CAST cDNA fragments were generated by PCR, subcboned into pXal, and expressed as 13-galactosidase fusion proteins in E. coli (Fig. 5) .In Western blot analysis, only clones that contained the C-terminal amino acids reacted with the index patient's serum (Figs. 5 and  6 ). The C-terminal fragment CA5T682_7#{216}8 reacted with all 16 sera tested,whereas only one serum also recognized another CAST fragment (CAST645689). This indicates that the major epitope is located within the C-terminal 27 amino acids of the protein.
To further characterize the epitope, fusion proteins with a modified CAST C-terminus were generated by PCR with mutant primers.The 13-galactosidase fusion protein contained residues 649-708 of human CAST. In one clone Lys706 was substituted by lIe (CASTK7O6I); in another, Asp707 was substituted by Ala (CASTD7O7).
The exchange of either of the two charged amino acids by an abiphatic residue abolished binding of the index patient's serum antibodies to the fusion protein (Figs. 5 and 7). Furthermore, antibody binding of23 of 24 anti-CASTpositive sera was abolished. The serum that was not affected was identical to the one that had an additional binding site in fragment CAST645_689. This experiment provided further evidence that the C-terminus of CAST contains the major epitope for autoantibodies.
In addition, it suggested that the two amino acids Lys706 and Asp707 are part of the antibody binding site. Numbers indicated for each fragment represent the CAST amino acids present in this particular fragment. The mutant clones
CASTK7O6I
and CASTO7O7A are also shown. In the left-hand column the primers used to generate the specific subclone are indicated. Only the clone CAST61245 was generated by restriction endonuclease digestion with EcoRI/Pstl from pUC18 containing the original insert. In the first column to the right, indicates a positive reaction in Western blots with the index patient's serum, and indicates a negative reaction. In the second column a summary of the reactivities of the other Western blot-positive sera is given. nd., not done. OnCASTe4ios IA), all tested sera, diluted 1:100, werepositive. Thesignalwas abolished in all sera except one (see text) by using the mutated fusion proteins CASTK7O6I (B) and CASTD7O7A (C).
DEVELOPMENT OF AN ANTI-CAST ELISA
Since the major epitope recognized by >90% of the sera with CAST autoantibodies could be located to the C-terminal 27 amino acids and perhaps even to the C-terminal 10 amino acids, we decided to develop an ELISA based on a synthetic peptide that consisted of these 27 amino acids (CAST682_708). This peptide was coated to microtiter plates as described in Materials and Methods. Sera were incubated at a dilution of 1:200 and the binding of autoantibodies to the peptide was detected by a peroxidase-conjugated anti-human IgG antibody. By varying the concentrations of the conjugate, the serum dilution, the blocking reagent, and the substrate, the background absorbance could be reduced to <0.010, while several positive samples had absorbances >1.000, so that a reasonable slope of the calibration curve isachieved (Fig.8) .The assayiscalibrated with a CAST autoantibody-positive recalcified plasma (donor H.K.) used at different concentrations from 1:50 to 1:1000. Arbitrary units (AU) were defined such that the absorbance at a dilution of 1:100 equals 100 AU and the absorbance at 1:1000 equals 10 AU, and so on. In the range 20-200 AU, the absorbance is linear to the logarithm of the antibody titer (Fig. 8 ). An even better curve-fitting can be achieved by a nonlinear procedure. The calibration of the ELISA with serum of donor H.K. was confirmed by two other high-titer sera (H.B., H.M.) used as a calibrator.
A total of 14 positive sera, ranging from 26 to 164 AU, were tested. and in a bow-titer serum the mean was 11 ± 0.6 AU (CV 5.6%). This shows that the assay is reproducible and precise. Particularly, in the normal range and the low abnormal range the and are well within the range for comparable assays. We next estimated a reference range of the assay for healthy blood donors. The mean age of this group was 26 years with a range from 18 to 55 years (n = 205). There were 113 men and 92 women in thisgroup. As expected,the distribution of the antibody titers was highly skewed to the left. Therefore the data were transformed logarithmically before further analysis. The cutoff was defined as the mean + 3 SD (derived from the transformed data), which represents 30 AU. When male and female blood donors were analyzed separately, slight differences were found for the calculated cutoff (28 AU and 32 AU, respectively).
However, these differences were due to a larger SD in women. This is rebated to the presence of five anti-CASTpositive sera in women compared with only two in men [3] . The authors speculate that CAST autoantibodies might be associated with immunologically induced infertility. However, no attempt was made to show an increased prevalence of CAST autoantibodies in infertile patients. Taking into account our data with regard to the prevalence of these autoantibodies in healthy persons, it could be just by coincidence that the CAST autoantibodies were found in infertile men.
In the studiesof Mimori etab.and Despr#{233}s et ab., anti-CAST antibodies were associated with RA [4, 5] . Approximately 50% of RA patients were positive for anti-CAST by Western blot. However, both studies are small, and the study by Mimori et al. [4] does not even include a healthy control group. Furthermore, there are some substantial discrepancies regarding the association of CAST autoantibodies to other autoimmune diseases, e.g., systemic lupus erythematosus. Whereas Despr#{233}s et al. [5] claim that among their patients with autoimmune diseases other than RA the prevalence of anti-CAST is low, Mimori et al. [4] describe an incidence >20% for several other autoimmune diseases. However, the latterauthors did not specifically describe under which conditions a sample was considered positive in their assay. These data clearly demonstrate that sufficiently barge numbers of patients have to be analyzed before definitive conclusions about the disease association of CAST autoantibodiescan be drawn. Furthermore, it is mandatory that reproducible tests are used that permit an unbiased determination of positive and negative samples. In our hands, the Western blot assay with lysates from recombinant bacteria did not meet these criteria. Apparently, Despr#{233}s et al. also had problems with the definition of a positive sample. They tried to circumvent part of this problem by performing duplicate determinations of samples and a third analysis in cases in which the two initial determinations did not yield the same result [5] . Such a procedure is clearly subject to a severe investigator bias, whereas the ELISA yields a numerical result, which permits an unbiased interpretation. The analysis of a large number of healthy persons provides an 
